| Gene name: | EZH2 |
| Aging type: | Accelerate |
| Aging characteristic: |
| Tissue type: | Human cartilage explants |
| Cell name: | Chondrocytes |
| Gene ID: | 2146 |
| Category: | protein coding |
| Phenotype: | Osteoarthritis |
| Experimental category: | L |
| PMID: | 33177650 |
| Experiment: | ELISA//RT-PCR//Safranin-O |
| Description: | We show that EPZ-6438 attenuated IL-1β-induced expression and release of MMP-1, -3 and -13 in chondrocytes, suggesting that this inhibitor could reduce chondrocyte catabolism. We confirmed this hypothesis using human cartilage explants. Safranin-O staining in explants treated with IL-1β for 48 h was less intense compared to untreated explants, showing that IL-1β induced a proteoglycan loss in cartilage. In the explants with the co-treatments of IL-1β with EPZ-6438, the safranin-O staining stayed intensively red, demonstrating that EPZ-6438 was able to preserve the proteoglycan content in the cartilage matrix, and consequently reduced cartilage degradation. |
| Target gene: | NGF |
| Official symbol(s): | NGF |
| R-AG-Target gene: | Upregulation |
| Subcategory: | Unclear |
| Target gene experiment: | RT-PCR |
| Target gene description: | We showed that EZH2 overexpression increases IL-1β-mediated NGF expression. We showed that EZH2 overexpression increases IL-1β-mediated NGF expression, while EPZ-6438 had the opposite effect and reduced IL-1β-induced expression of NGF. |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...